Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate

Jiang-Yi Wang; Guo-Peng Yu; Long Li; Guo-Wen Lin; Ding-Wei Ye

doi:10.1186/s40779-021-00364-x

Your Location：

Home >

Browse articles >

Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate

LETTER TO THE EDITOR | Updated：2023-03-20

- Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
- Military Medical Research Vol. 9, Issue 6, Pages: 754-756(2022)
- Affiliations：
  
  1.Department of Urology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai 200032, China
  2.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  3.Department of Urology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China
- Author bio：
  
  * guowenlin@urocancer.org;
  dwyeli@163.com
- Funds：
- DOI：10.1186/s40779-021-00364-x
  CLC：
- Published：2022-12
- Accepted：
Scan QR Code
Wang JY, Yu GP, Li L, Lin GW, Ye DW. Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate. Mil Med Res. 2022;9(1):5.
DOI：

Wang JY, Yu GP, Li L, Lin GW, Ye DW. Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate. Mil Med Res. 2022;9(1):5. DOI： 10.1186/s40779-021-00364-x.

摘要

Abstract

关键词

Keywords

references

Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA Cancer J Clin . 2018 ; 68 ( 6 ): 394 - 424 .

Fizazi K , Scher HI , Molina A , Logothetis CJ , Chi KN , Jones RJ , et al . Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study . Lancet Oncol . 2012 ; 13 ( 10 ): 983 - 92 .

de Bono JS , Logothetis CJ , Molina A , Fizazi K , North S , Chu L , et al . Abiraterone and increased survival in metastatic prostate cancer . N Engl J Med . 2011 ; 364 ( 21 ): 1995 - 2005 .

Scher HI , Morris MJ , Stadler WM , Higano C , Basch E , Fizazi K , et al . Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3 . J Clin Oncol . 2016 ; 34 ( 12 ): 1402 - 18 .

Rescigno P , Lorente D , Bianchini D , Ferraldeschi R , Kolinsky MP , Sideris S , et al . Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer . Eur Urol . 2016 ; 70 ( 5 ): 724 - 31 .

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Standardizing the classification of gastric cancer patients with limited and adequate number of retrieved lymph nodes: an externally validated approach using real-world data

Research on the Measurement System of the Attack Angle between Wheel and Rail Based on Image Identification

Experimental Research on the Maximum Tensile Force in Reinforced Abutment Reinforcement

Dynamic Stress Analysis on Speed-increase Subgrade of Existing Railway

Analysis on the Reason of Larger Wheel/Rail Lateral Force for Loaded Car with 3D-axle Welded-frame Bogies during Negotiating

Related Author

Wei Wang

Yu-Jie Yang

Ri-Hong Zhang

Jing-Yu Deng

Zhe Sun

Sharvesh Raj Seeruttun

Zhen-Ning Wang

Hui-Mian Xu

Related Institution

Department of Gastric Surgery, Sun Yat-sen University Cancer Center

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital

Department of Surgical Oncology, the First Hospital of China Medical University

⁰